Rhode Island Hospital

Running trials

• Not yet recruiting

  Tailored Education for Aging and Cognitive Health: A Health Behavior Change Intervention for Midlife Adults at Risk for Alzheimer's Disease and Related Dementias

  NCT07933367· Rhode Island Hospital· Source

• Not yet recruiting

  TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

  NCT07502872· Phase 2· Brown University· Source

• Recruiting

  A Study of DS-3939a in Participants With Solid Tumors

  NCT07739966· Phase 1/2· Daiichi Sankyo· Source

• Not yet recruiting

  Digital Intervention Delivered Via Street Medicine to Increase HIV and Substance Use Care Among Survivors of Sex Trafficking

  NCT07699484· Early phase 1· Lifespan· Source

• Recruiting

  Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

  NCT06917911· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

  NCT07437950· Phase 2· National Cancer Institute (NCI)· Source

• Not yet recruiting

  Nurse-Led PrEP Initiation Among Incarcerated Individuals

  NCT07781423· Rhode Island Hospital· Source

• Recruiting

  Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  NCT07805954· Phase 3· Revolution Medicines, Inc.· Source

• Not yet recruiting

  Verapamil Effect in Cystic Fibrosis-related Dysglycemia

  NCT07688070· Phase 2· Rhode Island Hospital· Source

• Recruiting

  A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

  NCT07466316· Phase 3· Children's Oncology Group· Source

• Not yet recruiting

  Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)

  NCT07601295· Phase 2· Stanford University· Source

• Recruiting

  Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  NCT07321652· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours of Last Known Well

  NCT07115940· Amrou Sarraj· Source

• Enrolling by invitation

  Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

  NCT06773936· Phase 2· SWOG Cancer Research Network· Source

• Recruiting

  Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  NCT07198074· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Peroneal Electrical Nerve Stimulation in Pregnancy for Restless Legs Syndrome

  NCT07144631· Rhode Island Hospital· Source

• Recruiting

  Testing for Safety and Colorectal Cancer Preventive Effects of ONC201

  NCT05630794· Phase 1· National Cancer Institute (NCI)· Source

• Recruiting

  IVUS CHIP UPP Registry

  NCT06625801· ECRI bv· Source

• Recruiting

  Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

  NCT06958328· Phase 3· NRG Oncology· Source

• Recruiting

  AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

  NCT06959524· Boston Scientific Corporation· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

  NCT06944522· Phase 3· BlueRock Therapeutics· Source

• Recruiting

  Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  NCT06317662· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT06124157· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  NCT06592924· Phase 3· Canadian Cancer Trials Group· Source

• Recruiting

  Rapid Evacuation and Access of Cerebral Hemorrhage Trial

  NCT06870812· Emory University· Source

• Recruiting

  A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

  NCT06901531· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  NCT06672146· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Prepping for The Talk: Helping Trusted Adults and Youth Talk About Sexual Health

  NCT07011563· Rhode Island Hospital· Source

• Active, not recruiting

  Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

  NCT06814145· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

  NCT06401330· Phase 3· Children's Oncology Group· Source

• Recruiting

  Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

  NCT06513962· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

  NCT06556563· Phase 3· NovoCure GmbH· Source

• Recruiting

  StrokeNet Thrombectomy Endovascular Platform

  NCT06289985· Medical University of South Carolina· Source

• Recruiting

  Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

  NCT06750185· Phase 1/2· BioNTech SE· Source

• Recruiting

  A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

  NCT06699212· Phase 3· Rakuten Medical, Inc.· Source

• Recruiting

  The Puerto Rico Asthma Integrated Response Program ("PR-AIR")

  NCT05999032· Rhode Island Hospital· Source

• Active, not recruiting

  Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

  NCT06632327· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Brain and Behavior Influences on Obesity Development From Infancy Through Childhood

  NCT06861868· Johns Hopkins University· Source

• Active, not recruiting

  Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

  NCT06498960· CereVasc Inc· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

  NCT06413706· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

  NCT06337318· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

  NCT06368817· Phase 2· Children's Oncology Group· Source

• Recruiting

  Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  NCT06317649· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  NCT05554406· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  NCT05554393· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass

  NCT07132788· University of Pennsylvania· Source

• Recruiting

  VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

  NCT06264180· Phase 3· Replimune, Inc.· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

  NCT06447662· Phase 1· Pfizer· Source

• Recruiting

  MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  NCT05564390· Phase 2· National Cancer Institute (NCI)· Source

Showing 50 of 194.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers27 recruiting
• Acute myeloid leukaemia10 recruiting
• Acute lymphoblastic leukaemia9 recruiting
• Lung cancer8 recruiting
• Stroke6 recruiting
• Sarcoma5 recruiting
• Coronary artery disease4 recruiting
• High blood pressure4 recruiting
• Ovarian cancer4 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Down syndrome3 recruiting
• HIV3 recruiting
• Kidney cancer3 recruiting
• Myelodysplastic syndromes3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Pancreatic cancer3 recruiting
• Pulmonary arterial hypertension3 recruiting
• Alzheimer disease2 recruiting
• Atrial fibrillation2 recruiting
• Colorectal cancer2 recruiting
• Cystic fibrosis2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Follicular lymphoma2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Head and neck cancer2 recruiting
• Mantle cell lymphoma2 recruiting
• Multiple myeloma2 recruiting
• Neuroblastoma2 recruiting
• Prostate cancer2 recruiting
• Triple-negative breast cancer2 recruiting
• Aortic stenosis1 recruiting
• Bladder cancer1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Endometrial cancer1 recruiting
• Frontotemporal dementia1 recruiting
• Glioblastoma1 recruiting
• Hearing loss1 recruiting
• Heart failure1 recruiting
• Hodgkin lymphoma1 recruiting
• Insomnia1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Obesity1 recruiting
• Parkinson disease1 recruiting
• Restless legs syndrome1 recruiting
• Thyroid cancer1 recruiting

Closed trials

• Completed

  A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

  NCT06881836· Phase 2· Ono Pharmaceutical Co., Ltd.· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· GB002, Inc.· Source

• Completed

  Study of DF6215 in Patients With Advanced Solid Tumors

  NCT06108479· Phase 1· Dragonfly Therapeutics· Source

• Completed

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· Phase 3· Amgen· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

  NCT05829226· Phase 1· PureTech· Source

• Completed

  Study of DF9001 in Patients With Advanced Solid Tumors

  NCT05597839· Phase 1/2· Dragonfly Therapeutics· Source

• Completed

  A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

  NCT05357989· Phase 3· Annovis Bio Inc.· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Gilead Sciences· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Biogen· Source

• Completed

  Impact of Sleep Duration on Immune Balance in Urban Children With Asthma

  NCT05420766· Rhode Island Hospital· Source

• Completed

  Effects of Tildrakizumab on Epigenetic Age

  NCT05110313· Phase 4· Carlos Wambier· Source

• Withdrawn

  Combined Injectable Treatment for HIV and OUD

  NCT05991622· Phase 2· Rhode Island Hospital· Source

• Terminated

  Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

  NCT05220722· Phase 1/2· TriSalus Life Sciences, Inc.· Source

• Completed

  A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

  NCT04945460· Phase 2· Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA· Source

• Terminated

  A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

  NCT03919162· Phase 2· Vivoryon Therapeutics N.V.· Source

• Completed

  Intelligent Spine Interface, Clinical (ISI-C)

  NCT04302259· Rhode Island Hospital· Source

• Completed

  A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

  NCT04921969· Phase 3· Incyte Corporation· Source

• Completed

  Removing Transfusion Dependence as a Barrier to Hospice Enrollment

  NCT05063591· Adam Olszewski· Source

• Completed

  Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy

  NCT04693715· Phase 2· Revalesio Corporation· Source

• Completed

  Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

  NCT04801420· Phase 2· Pfizer· Source

• Completed

  Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation

  NCT04702451· Volta Medical· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· NovoCure Ltd.· Source

• Completed

  A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

  NCT04640077· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy

  NCT04266795· Phase 2· Takeda· Source

• Completed

  A Study of DF6002 Alone and in Combination With Nivolumab

  NCT04423029· Phase 1· Dragonfly Therapeutics· Source

• Recruiting

  Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

  NCT04278404· Duke University· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source

• Recruiting

  Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

  NCT03907046· Phase 3· Yale University· Source

• Completed

  Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

  NCT03374332· Phase 1/2· Brown University· Source

• Completed

  Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

  NCT04166058· Phase 3· AbbVie· Source

• Completed

  Study of DF1001 in Patients With Advanced Solid Tumors

  NCT04143711· Phase 1/2· Dragonfly Therapeutics· Source

• Completed

  A Mobile Gaming App to Improve ART Adherence for Youth

  NCT03760211· Rhode Island Hospital· Source

• Completed

  Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

  NCT04026113· Phase 3· AbbVie· Source

• Completed

  Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

  NCT03702725· Phase 1· Alliance Foundation Trials, LLC.· Source

• Completed

  ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease

  NCT03622905· Functional Neuromodulation Ltd· Source

• Completed

  TRC-PAD Program: In-Clinic Trial-Ready Cohort

  NCT04004767· University of Southern California· Source

• Completed

  Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

  NCT03677154· Phase 1/2· Hoffmann-La Roche· Source

• Terminated

  Study of Probable Benefit of the Neuro-Spinal Scaffold™ in Subjects With Complete Thoracic AIS A Spinal Cord Injury as Compared to Standard of Care

  NCT03762655· InVivo Therapeutics· Source

• Completed

  Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung

  NCT03589547· Phase 2· Brown University· Source

• Completed

  Peer-Administered Asthma Self-Management Intervention in Urban Middle Schools

  NCT03446365· Rhode Island Hospital· Source

• Completed

  Prospective Collection of PillCam SB3 Videos and Raw Data Files for Future Developments (SODA)

  NCT03771508· Medtronic - MITG· Source

• Completed

  Rhode Island Asthma Integrated Response Program

  NCT03583814· Rhode Island Hospital· Source

• Completed

  A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

  NCT03474107· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· CSL Behring· Source

• Completed

  Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry

  NCT03048825· Phase 3· Population Health Research Institute· Source

• Completed

  Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors

  NCT03206450· Children's Oncology Group· Source

• Completed

  PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease

  NCT03168776· Sino Medical Sciences Technology Inc.· Source

• Completed

  Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

  NCT02873195· Phase 2· Academic and Community Cancer Research United· Source

• Completed

  Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

  NCT03072238· Phase 3· Hoffmann-La Roche· Source

Showing 50 of 82.

Conditions

Diseases this institution publishes on or runs trials for.

• Lyme disease3 works · 1 trial